CD274 and hematologic disorder: MYC regulates expression of PD-L1, while BET inhibitors were reported to down-regulate PD-L1 expression, which may have implications as immunotherapy or for immunotherapy-based combinations.86 There are several BET inhibitors currently being investigated in clinical trials, e.g., BMS-986158 in advanced solid tumors (NCT02419417), CPI-0610 in various myeloid malignancies (NCT02158858), and MK-8628 in hematological malignancies (NCT02698189).